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Currently, about two-thirds of hemodialysis patients
worldwide are treated with high-flux membranes. This is
most likely based on the assumption that the extended
solute clearance that can be obtained with more open
membranes will contribute to improved clinical outcome.
To have full advantage of convective solute removal,
hemodiafiltration offers a superior modality as compared
to both low-flux and high-flux hemodialysis. However, this
technique is offered to only a minority of patients. In this
review, we summarize the available clinical evidence on
hemodiafiltration and define still remaining questions.
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Hemodialysis (HD) using high-flux membranes is now well
accepted around the world (Figure 1). The rationale is that
it offers enhanced clearance of various uremic toxins by
combining diffusion with some degree of convective trans-
port within the dialyzer. This might be of relevance in
determining clinical outcome. However, two large rando-
mized trials failed to show survival benefit for the general
HD population, when high-flux dialysis was compared with
dialysis with standard low-flux membranes.1,2 Importantly,
both trials identified certain subgroups who did benefit. This
might be interpreted as showing that the intervention is not
powerful enough to affect all patients, but only certain high-
risk patients. Further, neither study suggested any harmful
effects associated with high-flux membranes. Therefore, it
seems justified to review the clinical data on hemodiafiltra-
tion (HDF), a technique that offers a greater advantage in
clearance of various types of uremic toxins than HD with
low- and high-flux membranes. In this article, we will address
this issue with an emphasis on studies applying online HDF,
because that technique has the potential to give the most
pronounced enhanced clearance as compared to standard
HD and other modes of HDF, and as a consequence the
greatest likelihood of providing benefit to the patient. In the
paragraph dealing with survival, studies on high-flux HD will
also be briefly discussed. High-flux HD can be considered as
a form of ‘low-dose’ HDF, in which the ultrafiltered volume
usually exceeds the desired weight loss, and is compensated
by backfiltration. HDF can be used for treatment of both
acute and chronic kidney failure and this article deals only
with the chronic therapy.
A problem when reviewing the available literature is
the lack of uniformity of the applied dialysis techniques,
which makes it especially difficult to perform a meta-analysis.
Furthermore, it is likely that effects will depend on the
‘dose’, that is the convection volume that is applied, and
different modes of therapy provide varying degree of
convective clearance. Online HDF has the potential to
provide the greatest convection volume, and postdilution
HDF is more likely to produce enhanced clearance than
predilution HDF. Therefore, different studies on HDF need
to be compared with caution as applied techniques and
delivered convection volumes can vary considerably between
clinical studies.
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In the next paragraphs, we will briefly touch upon some
technical issues, subsequently examples of clearance data and
available data on clinical effects are presented.
TECHNICAL ISSUES
The convective transport requires ultrafiltration of fluid to an
extent that exceeds the desired weight loss. Fluid balance is
maintained by infusion of a replacement fluid, also referred
to as substitution fluid. This fluid can be provided in
industrially prepared, autoclaved, plastic bags. This is
logistically troublesome and expensive, and as a consequence
not widely accepted. The fluid can also be generated as an
integral part of the treatment. This was first described by
Canaud et al.3 more than 2 decadeqs ago. Online HDF makes
use of quality-controlled, stepwise ultrafiltration. The
technical aspects of the production process are discussed in
more detail elsewhere.4,5 The substitution fluid is mixed with the
blood and should therefore be sterile and non-pyrogenic with a
composition similar to plasma water. Importantly, this high
quality needs to be continuously present. Recently, we showed
that by using modern equipment for water and fluid processing,
production of the fluid on a regular basis with optimal quality is
very well possible over a prolonged period of time.6,7
The fluid can be administered before the filter (predilu-
tion), after the filter (postdilution), or inside the filter
(high-flux dialysis and mid-dilution).5 Although predilution
is true dilution of the blood, postdilution is actually
replacement of ultrafiltered volume. With respect to toxin
removal, postdilution is more effective than predilution.
Mixed dilution is a combination of pre- and postdilution and
so is mid-dilution, a method that requires a special type of
filter where the fluid can be infused between two separate
fiber bundles.5,8–10
SOLUTE REMOVAL
Uremic toxins can be categorized into three groups: free
water-soluble low-molecular-weight solutes, such as urea and
creatinine; middle-sized solutes, such as b2-microglobulin
(b2m); and protein-bound solutes, such as p-cresol.
A switch from either low- or high-flux HD to online HDF
usually results in an increase in small solute clearance.11–15
The increase is modest because small solute clearance
is mainly diffusive and therefore already very effective
during HD.
The phosphate ion is small, but, being surrounded by
water molecules, it has a clearance profile similar to that of
middle molecules. Superior clearance of phosphate by HDF
as compared to standard HD has been shown in a number of
studies.14,16–18
The removal of b2m is clearly increased during online
HDF, and clearance of solutes in the middle molecule range
might be of clinical relevance.11–15,19 Predialysis b2m levels in
the HEMO study predicted mortality,20 and several observa-
tional and randomized studies have shown that predialysis
levels decrease when patients are switched to online
HDF.13,21,22 As indicated above, b2m removal correlates
with convection volumes of a single session. This effect is
most pronounced in patients without residual kidney
function.21–24
Other potentially relevant solutes more effectively cleared
by HDF include complement factor D13 and inflammatory
mediators such as cytokines.25 In a crossover study in which
patients went from high-flux HD to online HDF and back, it
was reported that online HDF markedly reduced production
of TNFa and IL-6 in addition to proinflammatory
CD14þCD16þ cells.26 Online HDF is also associated with
improvement of variables related to endothelial dysfunc-
tion,27 oxidative stress, and antioxidant capacity.28,29 Some
studies report reduction of inflammatory markers such as C-
reactive protein,30 whereas others find no such effect
compared to high-flux HD.31 The latter should be interpreted
as positive because it supports the idea that infusion of
considerable amounts of fluid is safe. Removal of certain
protein-bound solutes, of which p-cresol is an example, is
enhanced in some studies,32,33 but not in others.34 Data
suggest that enhanced clearance is caused by increase in
removal of the unbound fraction. Finally, online HDF has
been shown to reduce advanced glycation end-products more
effectively than high-flux dialysis.35
So, several lines of evidence indicate that use of online
HDF is associated with enhanced clearance not only of small
molecules, but also of several types of other molecules that
might be of relevance in the pathogenesis of uremic and
cardiovascular complications.11
CLINICAL VARIABLES
Because online HDF removes substances in a broader range
of molecular size compared to conventional low-flux HD, it
might therefore provide an improvement of clinically mean-
ingful variables. A number of studies suggest that online HDF
is associated with an improvement of hemodynamic stability
and blood pressure control,14,36–38 whereas others could not
confirm this.31 The application of online hemofiltration is
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Figure 1 |Distribution of the use of various forms of dialysis
therapy. Data provided by Gambro. HD, hemodialysis;
HDF, hemodiafiltration; HF, hemofiltration.
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also associated with improved hemodynamic stability.39 The
difference in hemodynamic stability disappeared when online
HDF was compared with temperature-controlled HD. Thus,
this effect, which is a useful feature, seems to be mainly
caused by cooling of the blood by enhanced thermal energy
losses within the extracorporeal system in online HDF rather
than from increasing solute removal.37,40
Several nonrandomized trials have reported decreased
erythropoietin resistance in patients treated with online
HDF.31,41–43 In this respect, the removal of poorly defined
erythropoiesis-inhibiting factors and the creation of a more
biocompatible environment with less inflammatory stimuli,
possibly also by the use of ultrapure dialysis fluid, might have
a role. However, a randomized trial was not able to confirm
these data, although the study was not specifically designed to
answer this question.13
Improvement of nutritional parameters has been reported
in patients switched to online HDF.14,44 Quality of life has
been evaluated in a small number of studies and no or some
effect was found.13,14 However, it is likely that the available
studies were not adequately powered for these clinical
variables. In the absence of a survival benefit, a positive
effect on quality of life might still be a reason to favor online
HDF. Therefore, it seems important to address the question
whether online HDF shows any benefit on quality of life as
compared to standard HD. Quality of life is presently studied
in prospective randomized fashion.45,46
In conclusion, the use of online HDF is associated with
positive effects on a number of important clinical variables,
although some of the data come from small and insufficiently
powered studies.
SURVIVAL
The hypothesis that the extended removal of larger solutes
obtained with high-flux membranes might result in im-
provement of hard clinical end points, has been tested in a
number of trials (Table 1).
The HEMO study compared low- and high-flux HD and
showed no difference in survival between the two groups.
However, significant risk reductions in death from cardiac
causes and in the combined outcome of first hospitalization
for cardiac causes or death from cardiac causes were
observed.1 In this prospective clinical trial, 1800 prevalent
patients on HD were randomized to either low- or high-flux
membranes with a mean follow-up of almost 3 years. One
subgroup analysis of this study suggests a survival benefit of
high-flux membranes for patients who at baseline are on HD
for more than 3.7 years.1 Another post hoc subanalysis
suggested a decreased risk of death from cerebrovascular
disease for patients on high-flux HD without baseline
evidence of cerebrovascular disease.47
Recently, the European Membrane Permeability and ESRD
Patient Outcome study, originally designed to study the effect
of membrane flux on outcome in hypoalbuminemic patients
on HD, showed a survival advantage in this group if they
were treated with high-flux membranes. However, the study
was amended underway due to slow enrollment so that the
study protocol was opened to normoalbuminemic subjects as
Table 1 | Some recent and ongoing studies evaluating effect of convective therapy as compared to standard HD on major
clinical end points
Reference Design
Intervention/
therapies
Number of
patients
Effect/primary
end point Remarks
HEMO study1,47 RCT High-flux low-flux HD 1846
921 on high-flux
No difference Positive effect of
high-flux in subgroup
MPO study2 RCT High-flux low-flux HD 647
318 on high-flux
No difference Positive effect of
high-flux in subgroup
Subanalysis of 4D study48 RCT Study on effect of statin 648
241 on high-flux
Improved survival
in high-flux (41%)
Post hoc analysis
Chauveau et al.49 Prospective
observational
High-flux low-flux HD 650
305 on high-flux
Improved survival
in high-flux (38%)
DOPPS51 Prospective
observational
HD HDF 2165
263 on HDF
Improved survival
in HDF (35%)
Only in infusate
415 l per session
EuCliD52 Retrospective
observational
HD olHDF 2564
394 on HDF
Improved survival
in HDF (37%)
Bosch et al.53 Retrospective
observational
HD HDF (double high-flux) 183
Approximately 25 on HDF
Improved survival
in HDF (60%)
Control based on
USRDS data
RISCAVID study54 Prospective
observational
HD HDF 757
303 on HDF
Improved survival
in HDF (22%)
Santoro et al.55 RCT HD HF 64
32 on HF
Improved survival
in HF
Small study
Vilar et al.30 Retrospective
observational
HD HDF 858
232 on HDF
Improve survival
in HDF (34%)
Predominantly
on HDF
CONTRAST45,46 RCT HD olHDF Target approx 700 All cause mortality Ongoing
Canaud et al.57 RCT HD olHDF Target approx 600 Intradialytic morbidity Ongoing
Italian study58 RCT HD olHDF olHF 146 Hemodynamic stability Ended
Abbreviations: HD, hemodialysis; HDF, hemodiafiltration; HF, hemofiltration; olHDF, online hemodiafiltration; RCT, randomized controlled trial.
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well. In the overall group (containing hypoalbuminemic and
normoalbuminemic patients) no survival advantage for
patients treated with high-flux dialysis could be observed.
For diabetic patients there was a survival advantage when
high-flux HD was used, both for the overall and the
hypoalbuminemic group.2
Two large studies have shown a considerable beneficial
effect of high-flux membranes. A post hoc analysis of the 4D
study, which was designed to analyze the effect of atorvastatin
in diabetic chronic patients on HD on the composite end
point of cardiovascular mortality and morbidity, showed a
superior survival in patients continuously treated with high-
flux as compared to low-flux membranes.48 Finally, a large
observational study in France showed that the use of high-
flux membranes was significantly associated with improved
survival.49
A Cochrane review of 20 studies on patients on HDF,
hemofiltration, and HD examined various end points,
including mortality.50 The meta-analysis on mortality
(pooled sample size 388 patients) showed no difference.
However, mortality rates were low, the included studies
showed many design differences and the only conclusion that
could be made was that more randomized controlled studies
are needed to address this question.
Several retrospective analyses of patients treated with HDF
suggest that there might be a survival benefit. The use of
high-efficiency HDF in the DOPPS cohort (replacement
volume of more than 15 l per session, which means online
HDF in most cases for obvious logistical reasons) was
associated with a 35% lower mortality risk, even after
correction for various confounding factors.51 In contrast,
low-efficiency HDF (replacement volume less than 15 l per
session) was not associated with any significant reduction of
risk. Another large observational study from Eastern Europe
reported 37% mortality risk reduction in patients on online
HDF.52 In a single-center retrospective analysis from the
United States, the standardized mortality ratio for patients
treated with HDF (double high-flux HDF) was 0.41,
indicating an almost 60% lower risk of mortality.53 A large
Italian observational study again suggests a survival benefit in
patients on online HDF.54 Very recently a UK dialysis unit
with long experience of HDF reported the outcome from
some 150,000 sessions of online HDF compared with twice as
many sessions of high-flux HD.30 The patients predomi-
nantly treated with HDF had a 34% lower mortality risk.
Finally, a recent randomized trial reported a survival benefit
for patients on online hemofiltration.55 The study had
sufficiently long follow-up, but showed some important
limitations in size and power.
In view of the evidence outlined above, it seems reasonable
to hypothesize that online HDF offers a superior treatment
modality as compared to standard HD therapy.
ONGOING STUDIES
The Convective Transport Study (CONTRAST) is a pros-
pective randomized international (mainly in the Netherlands,
also in Norway and Canada) trial on the effect of online HDF
on all cause mortality and cardiovascular morbidity and
mortality. According to the main hypothesis, better clearance of
middle molecule waste substances results in a better correction
of the uremic environment, ultimately leading to a reduction
in all cause mortality and cardiovascular morbidity and
mortality. On the basis of a 20% reduction of the primary
end point, approximately 700 patients need to be enrolled. At
the time of writing (October 2009), approximately 700
patients have been included in more than 25 centers and they
will be followed until the end of 2010. Patients on standard
low-flux HD with an adequate spKt/Vurea are randomized to
online HDF or standard HD. For HDF, target substitution
volume is 6 l/h in the postdilution mode. Rationale and
design of the study are presented elsewhere.45,46 Quality of life
and a formal cost effectiveness analysis are also included in
CONTRAST. Our experience so far shows that the target of 6 l/h
is sometimes difficult to achieve, but that 415 l/4 h is possible
in the vast majority of patients.56 Switch to online HDF results
in a 20–25% drop in predialysis b2m levels, especially in patients
suffering from anuria, who have higher initial plasma levels of
b2m than patients with still some urinary output.
In a French prospective randomized trial, HDF is
compared to high-flux HD in 600 patients older than
65 years who are followed for 2 years. Primary end point is
intradialytic morbidity (hypotension and symptoms),
whereas secondary end points are all cause and cardiovas-
cular mortality and laboratory markers of lipid metabolism,
oxidative stress, and inflammation.57 At the time of writing,
250 patients have been included and much effort is invested
into reaching the target number of patients.
In a recently completed Italian study, 146 chronic patients
on HD were randomized to either a convective therapy
(predilution HDF (25%) or HF (25%)), or low-flux HD
(50%), with a follow-up period of 2 years. Hemodynamic
stability and blood pressure control were studied as primary
outcomes, whereas secondary outcomes were morbidity and
overall and cardiovascular mortality.58 The results of this
study are soon to be expected.
Finally, two studies comparing HD and online HDF
are reported to be ongoing in Turkey and Spain (resp.
ClinicalTrials.gov: NCT00411177 and NCT00694031) with no
further information available.
PRACTICAL ISSUES
Not surprisingly, there might be a dose–effect relation when
applying HDF as a therapy. In other words, a certain
minimum ‘dose’ of convection volume is needed to obtain a
beneficial effect. Measuring b2m levels to quantify removal
and adjusting convection volumes accordingly, seems a
logical approach. However, the plasma levels of b2m may
not be an appropriate measure to guide therapy, because they
are determined substantially by factors other than the
extracorporeal clearance, that is residual kidney function
and inflammatory state. The only data linking variables of
convective transport to meaningful clinical end points are the
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DOPPS data.51 These results suggest that the dose of
convection volume should be between 17 and 27 l per session
(i.e. 15–25 l of substitution fluid and an average of 2 l of
desired weight loss). Some dialysis patients may benefit more
than others from treatment with this form of therapy, for
example, anuric dialysis patients who have more elevated
b2m levels than patients with still some urinary output. Thus,
HDF treatment may be of special benefit to patients who
have already experienced or who may need long-term
dialysis, as indicated by the results from the HEMO study.1
A summary of factors that determine ultrafiltration and as
a consequence the size of the convection volume was recently
reported by Penne et al.56,59 Modifiable treatment-related
factors include the obvious such as treatment time and
extracorporeal blood flow. In addition, hematocrit is an
important factor. Within the hematocrit range presently
advised by Guidelines, the relation between ultrafiltration
rate, that is convection, and extracorporeal blood flow rate
can be 25–35%. Some practical advise is given in Table 2 and
summarized elsewhere,59 which may guide the clinician to
perform online HDF in everyday clinical practice.
Although postdilution HDF may be associated with
increased risk of coagulation, likely caused by hemoconcen-
tration within the filter, online HDF may be used to avoid
such risk by being applied in predilution mode. With online
HDF the heparin dose can be minimized, anticoagulant risk
can be reduced, and even heparin-free dialysis for high-risk
patients is becoming practically and easily applicable.60,61
An important question is whether increasing the convec-
tion volume, within or beyond the range mentioned above,
would increase the removal of b2m and other relevant toxins.
Modeling suggests that b2m levels are only marginally
affected within this range due to the relative resistance of
b2m to transfer between body compartments.
62 It is likely
that increasing frequency of treatment sessions is more
effective than improving individual sessions per se.
DRAWBACKS
When discussing high-volume convective removal, it is
difficult to exclude the possibility or risk that useful
solutes are also removed. However, there are virtually no
data that address this issue although very high volume
exchange has been studied.63 Albumin loss is dependent on
the type of membrane and the transmembrane pressure
regime used by the method. As an example, the same high-
flux membrane used in postdilution or mid-dilution versus
predilution mode may increase the albumin loss up to five
times.64 Alternatively, transmembrane pressure control such
as performed in mixed HDF may reduce albumin loss by
50%.8 Whether this albumin loss is harmful or even
beneficial, is unclear.65
Not to a surprise, vitamin C is removed by HDF (as it is by
standard HD) and needs to be supplemented.66 Unexpect-
edly, blood levels of vitamin B12, often used as an example of
middle sized molecules, and folates did not change during
online HDF.66
PERSPECTIVE
In a recent survey among more than 6000 nephrology
professionals, almost equal percentages favored the use of
high-flux HD and HDF as their best option for extracorpor-
eal dialysis therapy.67 Regional comparisons showed that
Europeans favor HDF over high-flux HD and in the rest of
the world it was the other way around. In 2008 approximately
60% of dialysis membranes sold in Western Europe were of
the high-flux type (data from Fresenius, Bad Homburg,
Germany and Gambro, Lund, Sweden), but less than a
quarter of these were used in the convective therapies HDF or
HF (Figure 1). The rest were used in high-flux dialysis that is
characterized by backfiltration of a substantial, but un-
controllable, unpredictable and immeasurable volume of
dialysate directly into the patient. Therefore, it is necessary to
apply the same chemical and microbiological quality levels
for the dialysis fluid as when online HDF is performed. If that
is not the case, the use of high-flux HD might even be
harmful. If one accepts this last condition, it seems logical to
offer online HDF instead, because in that case the additional
costs are limited. For the dialysis community this might
mean a real upgrading of the therapy quality.
CONCLUSIONS
It seems fair to conclude that combining diffusive and
convective strategies offers an interesting option. The
standard use of high-flux membranes in HD, which can be
considered as a ‘poor man’s HDF’, is now widely accepted.
The combination of diffusive and convective transport can
most efficiently be obtained by applying online HDF, because
it can provide larger convection volumes without major
practical and economic constraints. The only data relating
dose, that is convection volume per session, with clinical
outcome, is provided by DOPPS. Presently available water
treatment equipment and dialysis machines make it possible
to perform online HDF on considerable scale in everyday
clinical practice and the main dialysis industries offer suitable
equipment. There are clear guidelines for the microbiological
and chemical quality of the infusate.
Table 2 | Basic requirements to perform effective online
hemodiafiltration in everyday clinical practice
Equipment
High-flux membranes
Ultrapure dialysis fluid
Sterilizing ultrafilter as final filter
Dialysis machine approved for online fluid preparation
Treatment variables
Blood flow X300ml/min, preferably 350–400ml/min
Dialysis fluid flow rate X500ml/min in postdilution and
correspondingly higher in predilution
Convection volume X17 l per session in postdilution and
correspondingly higher in predilution
Organization
Established routines for periodical evaluation of microbiological quality
of water and dialysis fluid
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There are data suggesting that online HDF may have a
beneficial effect on survival. Properly designed prospective
clinical trial(s) to prove this benefit are underway and will
hopefully provide useful information. Also, effects on quality
of life need to be evaluated. This is of importance because in
the absence of a clear effect on mortality, improved quality of
life might still be a reason to choose this therapy. Further, a
formal cost-effectiveness analysis is still required.
Admittedly, some important questions remain to be
addressed (Table 3). Other more intensive forms of dialysis
therapy, such as daily/nocturnal HD, might give results
superior to thrice weekly online HDF.68 However, it is
important to realize that online HDF is the only option that
results in measurable reduction in middle molecule waste
products, possibly relevant in determining clinical outcome,
within treatment schedules presently considered as ‘standard’
(i.e. three times 4 h per week). This makes it an attractive
option in existing organizational infrastructure.
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